DISPATCHES FROM INTERPHEX

Kemwell Talks Expansion and Approvals in India and the US

- Last updated on GMT

Related tags: Economics, India

At this year’s Interphex, Kemwell Biopharma spoke to Outsourcing-Pharma.com about recent expansions in both India and the US.

Kemwell’s Director of Corporate Development Christian Ahlmark, spoke about the FDA approval at its manufacturing plant in Bangalore, India as well as the biologics facility - also in Bangalore – that recently opened its doors.

Kemwell recently announced 1500 sq ft of analytical lab space had been added​ in response to a contract by a major manufacturer.

However, it is not just India where Kemwell has been expanding. Ahlmark said the company was expanding its “lab footprint”​ on the East Coast in order to offer its current customers formulation development, expertise, analyticals and project management services.

Related news

Show more

Related products

show more

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us

Products

View more

Webinars